March Biosciences Inc
Publicly observedHouston, United States
Seen in a public record (e.g. a government grant database); not otherwise verified.
Details and provenance
| Item | Value | Source | Status |
|---|---|---|---|
| Country | US | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| City / locality | Houston | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| Name | March Biosciences Inc | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
| UEI (U.S. federal entity ID) | TB1TRLB85UY7 | NIH RePORTER (opens in a new tab) 28 Sept 2026 | Publicly observed |
Recorded events
- Grant22 Sept 2026Publicly observed
NIH SBIR/STTR award: Overcoming Immune Evasion in Hepatocellular Carcinoma with Engineered T-Cell Therapy
USD 399,003.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2025Publicly observed
NIH SBIR/STTR award: A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma
USD 1,124,607.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Jul 2025Publicly observed
NIH SBIR/STTR award: A Phase 2 multi-center trial of CD5 CAR T-cell therapy in patients with T-cell lymphoma
USD 1,124,607.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
- Grant1 Sept 2024Publicly observed
NIH SBIR/STTR award: Dual-targeting allogeneic CAR T-cells for universal therapy of T-cell malignancies
USD 986,080.00 · National Cancer Institute · Source: NIH RePORTER (opens in a new tab)
Information only — not investment advice or an endorsement. Is this your company? Submit or update its details or request a correction.